Vaxil Bio Ltd.
VXL.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.20K | 26.70K | 48.80K | 21.40K | 32.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.20K | 26.70K | 51.60K | 22.90K | 32.30K |
| Operating Income | -23.20K | -26.70K | -51.60K | -22.90K | -32.30K |
| Income Before Tax | -14.50K | 26.00K | -48.80K | -15.70K | -26.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.50K | 26.00K | -48.80K | -15.70K | -26.40K |
| Earnings from Discontinued Operations | -- | 4.30K | -- | -- | -9.50K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.50K | 30.40K | -48.80K | -15.70K | -35.90K |
| EBIT | -23.20K | -26.70K | -51.60K | -22.90K | -32.30K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | 0.01 | -0.02 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.01 | -0.01 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | 0.01 | -0.02 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.01 | -0.01 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 2.74M | 2.74M | 2.74M | 2.74M | 2.74M |
| Average Diluted Shares Outstanding | 2.74M | 2.74M | 2.74M | 2.74M | 2.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |